FR2780069B1 - Famille de sequences nucleiques et de sequences proteiques deduites presentant des motifs retroviraux endogenes humains et leurs applications - Google Patents

Famille de sequences nucleiques et de sequences proteiques deduites presentant des motifs retroviraux endogenes humains et leurs applications

Info

Publication number
FR2780069B1
FR2780069B1 FR9807920A FR9807920A FR2780069B1 FR 2780069 B1 FR2780069 B1 FR 2780069B1 FR 9807920 A FR9807920 A FR 9807920A FR 9807920 A FR9807920 A FR 9807920A FR 2780069 B1 FR2780069 B1 FR 2780069B1
Authority
FR
France
Prior art keywords
sequences
deducted
family
patterns
applications
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
FR9807920A
Other languages
English (en)
French (fr)
Other versions
FR2780069A1 (fr
Inventor
Patrick M Alliel
Jean Pierre Perin
Francois Rieger
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Institut National de la Sante et de la Recherche Medicale INSERM
Original Assignee
Institut National de la Sante et de la Recherche Medicale INSERM
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to FR9807920A priority Critical patent/FR2780069B1/fr
Application filed by Institut National de la Sante et de la Recherche Medicale INSERM filed Critical Institut National de la Sante et de la Recherche Medicale INSERM
Priority to EP08010138A priority patent/EP1997895A1/fr
Priority to AU43751/99A priority patent/AU4375199A/en
Priority to CA2331923A priority patent/CA2331923C/fr
Priority to JP2000556036A priority patent/JP2002518051A/ja
Priority to DE69939114T priority patent/DE69939114D1/de
Priority to EP99926538A priority patent/EP1090122B1/fr
Priority to PCT/FR1999/001513 priority patent/WO1999067395A1/fr
Priority to US09/719,554 priority patent/US6919438B1/en
Publication of FR2780069A1 publication Critical patent/FR2780069A1/fr
Application granted granted Critical
Publication of FR2780069B1 publication Critical patent/FR2780069B1/fr
Priority to US11/028,539 priority patent/US7534439B2/en
Priority to US12/336,813 priority patent/US20090263783A1/en
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56983—Viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4713—Autoimmune diseases, e.g. Insulin-dependent diabetes mellitus, multiple sclerosis, rheumathoid arthritis, systemic lupus erythematosus; Autoantigens
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/70—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving virus or bacteriophage
    • C12Q1/701—Specific hybridization probes
    • C12Q1/702—Specific hybridization probes for retroviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/10022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Hematology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Urology & Nephrology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Wood Science & Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cell Biology (AREA)
  • Neurology (AREA)
  • Pathology (AREA)
  • Rehabilitation Therapy (AREA)
  • Rheumatology (AREA)
  • Toxicology (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
FR9807920A 1998-06-23 1998-06-23 Famille de sequences nucleiques et de sequences proteiques deduites presentant des motifs retroviraux endogenes humains et leurs applications Expired - Lifetime FR2780069B1 (fr)

Priority Applications (11)

Application Number Priority Date Filing Date Title
FR9807920A FR2780069B1 (fr) 1998-06-23 1998-06-23 Famille de sequences nucleiques et de sequences proteiques deduites presentant des motifs retroviraux endogenes humains et leurs applications
US09/719,554 US6919438B1 (en) 1998-06-23 1999-06-23 Nucleic sequence and deduced protein sequence family with human endogenous retroviral motifs, and their uses
CA2331923A CA2331923C (fr) 1998-06-23 1999-06-23 Famille de sequences nucleiques et de sequences proteiques deduites presentant des motifs retroviraux endogenes humains, et leurs applications
JP2000556036A JP2002518051A (ja) 1998-06-23 1999-06-23 ヒト内因性レトロウイルスモチーフを有する核酸及び推定されるタンパク質配列のファミリーのならびにその使用
DE69939114T DE69939114D1 (de) 1998-06-23 1999-06-23 Nukleinsäuresequenzfamilie und entsprechende proteinsequenzen, die humane endogene retrovirale motive enthalten, und ihre anwendungen
EP99926538A EP1090122B1 (fr) 1998-06-23 1999-06-23 Famille de sequences nucleiques et de sequences proteiques deduites presentant des motifs retroviraux endogenes humains, et leurs applications
EP08010138A EP1997895A1 (fr) 1998-06-23 1999-06-23 Famille de séquences nucléiques et de séquences protéiques déduites presentant des motifs rétroviraux endogènes humains, et leurs applications
AU43751/99A AU4375199A (en) 1998-06-23 1999-06-23 Nucleic sequence and deduced protein sequence family with human endogenous retroviral motifs, and their uses
PCT/FR1999/001513 WO1999067395A1 (fr) 1998-06-23 1999-06-23 Famille de sequences nucleiques et de sequences proteiques deduites presentant des motifs retroviraux endogenes humains, et leurs applications
US11/028,539 US7534439B2 (en) 1998-06-23 2005-01-05 Nucleic sequence and deduced protein sequence family with human endogenous retroviral motifs, and their uses
US12/336,813 US20090263783A1 (en) 1998-06-23 2008-12-17 Nucleic sequence and deduced protein sequence family with human endogenous retroviral motifs, and their uses

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR9807920A FR2780069B1 (fr) 1998-06-23 1998-06-23 Famille de sequences nucleiques et de sequences proteiques deduites presentant des motifs retroviraux endogenes humains et leurs applications

Publications (2)

Publication Number Publication Date
FR2780069A1 FR2780069A1 (fr) 1999-12-24
FR2780069B1 true FR2780069B1 (fr) 2002-06-28

Family

ID=9527737

Family Applications (1)

Application Number Title Priority Date Filing Date
FR9807920A Expired - Lifetime FR2780069B1 (fr) 1998-06-23 1998-06-23 Famille de sequences nucleiques et de sequences proteiques deduites presentant des motifs retroviraux endogenes humains et leurs applications

Country Status (8)

Country Link
US (3) US6919438B1 (enExample)
EP (2) EP1997895A1 (enExample)
JP (1) JP2002518051A (enExample)
AU (1) AU4375199A (enExample)
CA (1) CA2331923C (enExample)
DE (1) DE69939114D1 (enExample)
FR (1) FR2780069B1 (enExample)
WO (1) WO1999067395A1 (enExample)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2206785A1 (en) 1998-12-31 2010-07-14 Novartis Vaccines and Diagnostics, Inc. Improved expression of HIV polypeptides and production of virus-like particles
JP2003523721A (ja) 1998-12-31 2003-08-12 カイロン コーポレイション 抗原性ｈｉｖｃ型ポリペプチドをコードするポリヌクレオチド、ポリペプチド、およびそれらの使用
JP2003512844A (ja) * 1999-10-28 2003-04-08 ユニヴェルシテ・ドゥ・ジュネーブ 多発性硬化症関連スーパー抗原
FR2805279B1 (fr) * 2000-02-23 2004-09-24 Jean Jacques Guilhou Sequences retrovirales associees a des affections cutanees
US20070249808A1 (en) * 2000-10-30 2007-10-25 Bernard Conrad Multiple Sclerosis-related superantigen
WO2003004620A2 (en) 2001-07-05 2003-01-16 Chiron, Corporation Polynucleotides encoding antigenic hiv type c polypeptides, polypeptides and uses thereof
US20030170614A1 (en) 2001-08-31 2003-09-11 Megede Jan Zur Polynucleotides encoding antigenic HIV type B polypeptides, polypeptides and uses thereof
AT411262B (de) 2001-09-27 2003-11-25 Wolff Klaus Dr Humanes endogenes retrovirus
FR2865403B1 (fr) * 2004-01-23 2009-06-12 Biomerieux Sa Composition pour le traitement d'une pathologie associee a la msrv/herv-w
WO2005095442A1 (en) * 2004-03-30 2005-10-13 Institut Gustave Roussy Polypeptide sequence involved in the modulation of the immunosuppresive effect of viral proteins
US8680065B2 (en) * 2008-09-11 2014-03-25 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Oligonucleotides of human endogenous retrovirus 9 (ERV-9) long terminal repeat (LTR) and methods of use
EP3676285B1 (en) * 2017-09-01 2025-11-05 InProTher ApS A vaccine for use in the prophylaxis and/or treatment of a disease
JP7344300B2 (ja) 2018-09-18 2023-09-13 ブイエヌブイ ニューコ インク． Ａｒｃベースのカプシドおよびその使用
JP2022536364A (ja) 2019-06-13 2022-08-15 ザ ジェネラル ホスピタル コーポレイション 操作されたヒト内在性ウイルス様粒子および細胞への送達のためのその使用方法
CN110470837B (zh) * 2019-08-30 2022-09-16 苏州西山生物技术有限公司 利用猴srv病毒gp20蛋白检测猴srv病毒的方法及其试剂盒
US11129892B1 (en) 2020-05-18 2021-09-28 Vnv Newco Inc. Vaccine compositions comprising endogenous Gag polypeptides
WO2022020800A2 (en) 2020-07-24 2022-01-27 The General Hospital Corporation Enhanced virus-like particles and methods of use thereof for delivery to cells
US20240325535A1 (en) * 2021-11-11 2024-10-03 The Trustees Of The University Of Pennsylvania Compositions and methods comprising car t cells comprising prdm1 and/or nr4a3 knockout

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2233936T3 (es) * 1994-02-04 2005-06-16 Bio Merieux Virus msrv1 asociado a la esclerosis en placas, sus constituyentes nucleicos y sus aplicaciones.
FR2737500B1 (fr) 1995-08-03 1997-08-29 Bio Merieux Materiel viral et fragments nucleotidiques associes a la sclerose en plaques, a des fins de diagnostic, prophylactiques et therapeutiques
US5708157A (en) * 1996-07-26 1998-01-13 Genetics Institute, Inc. Secreted proteins and polynucleotides encoding them
US6312921B1 (en) * 1996-07-26 2001-11-06 Genetics Institute, Inc. Secreted proteins and polynucleotides encoding them
CA2272845C (en) * 1996-11-26 2010-01-12 Bio Merieux Viral material and nucleotide fragments associated with multiple sclerosis, for diagnostic, prophylactic and therapeutic purposes
FR2765588A1 (fr) * 1997-07-07 1999-01-08 Bio Merieux Materiel nucleique retroviral et fragments nucleotidiques notamment associes a la sclerose en plaques et/ou la polyarthrite rhumatoide, a des fins de diagnostic, prophylactiques et therapeutiques
ATE346153T1 (de) * 1997-07-07 2006-12-15 Bio Merieux Endogene retrovirale sequenzen, verwandten mit auto-immune krankheiten oder mit schwangerschaftsstörungen

Also Published As

Publication number Publication date
DE69939114D1 (de) 2008-08-28
JP2002518051A (ja) 2002-06-25
CA2331923C (fr) 2014-02-18
CA2331923A1 (fr) 1999-12-29
FR2780069A1 (fr) 1999-12-24
WO1999067395A1 (fr) 1999-12-29
EP1090122B1 (fr) 2008-07-16
US20090263783A1 (en) 2009-10-22
US20050118573A1 (en) 2005-06-02
US7534439B2 (en) 2009-05-19
AU4375199A (en) 2000-01-10
EP1997895A1 (fr) 2008-12-03
EP1090122A1 (fr) 2001-04-11
US6919438B1 (en) 2005-07-19

Similar Documents

Publication Publication Date Title
FR2780069B1 (fr) Famille de sequences nucleiques et de sequences proteiques deduites presentant des motifs retroviraux endogenes humains et leurs applications
PT1108039E (pt) Genes de alongases e suas utilizações
DE69823214D1 (de) Kit zur Längenbestimmung von Kathetern vor ihrer Einführung
NO20001458D0 (no) Behandling av opposisjonstrassforstyrrelse
DE69814069D1 (de) Neuartige form von s-omeprazol
DE69131935D1 (de) Bestimmung von DNS-Sequenzen
IS5413A (is) Tálmun oxunar fituprótína
EE9900357A (et) Geenisekvenaator ja meetodid
DE69721533D1 (de) Bekleidungsstück
PT1032396E (pt) Esterilizacao de glucocorticoesteroides
NO983364L (no) Konsensusproteiner
TR199501441A2 (tr) Islevsel poliorganosiloksanlar ve bunlarin hazirlanmasina mahsus islemlerden bir tanesi.
DE69930647D1 (de) Struktur-analoga von amin-basen und nucleosiden
PT1017408E (pt) Utilizacao de tetra-hidrolipstatina no tratamento de diabetes de tipo ii
ATE264069T1 (de) Verstärkung von nahrungsmitteln
EP0996433A4 (en) Methods for treatment of conditions associated with lactosylceramide
DE69934889D1 (de) Herstellung und reinigung von diboranen
DE69816046D1 (de) Zusammensetzung auf basis von hexanitrohexaazaisowurtizitan und hexanitrohexaazaisowurtizitan enthaltende sprengstoffzusammensetzung
DE69810499D1 (de) Behandlung von industriegeweben
DE69918447D1 (de) Antivirale kombinationen von lamivudin und adefovir
DE69927626D1 (de) Ausführung von Permutationen
DE69923829D1 (de) Zusammensetzung von nucleinsäuren und acemannan
DE69521513D1 (de) Herstellung von keramischen artikeln
DE69811864D1 (de) Herstellung von bandförmigen werkstücken
DE69726667D1 (de) Formloses Abfasen von Katheter

Legal Events

Date Code Title Description
PLFP Fee payment

Year of fee payment: 18

PLFP Fee payment

Year of fee payment: 19

PLFP Fee payment

Year of fee payment: 20